Effects of Psilocybin in Concussion Headache

Last updated: October 11, 2023
Sponsor: Yale University
Overall Status: Terminated

Phase

1

Condition

Headaches

Pain (Pediatric)

Pain

Treatment

Low Dose Psilocybin

High Dose Psilocybin

Placebo oral capsule

Clinical Study ID

NCT03806985
1607018057.B
  • Ages 21-65
  • All Genders

Study Summary

The purpose of this study is to investigate the effects of oral psilocybin in post-traumatic headache. Subjects will be randomized to receive placebo, low dose psilocybin, or high dose psilocybin on two separate test days approximately 14 days apart. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. Blood samples will be drawn at various timepoints to measure levels of inflammatory peptides.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of post-traumatic headache
  • Typical pattern of headache attacks with approximately two attacks or more weekly
  • Attacks are managed by means involving no more than twice weekly triptan use

Exclusion

Exclusion Criteria:

  • Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)
  • Axis I psychotic disorder in first degree relative
  • Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, orserious central nervous system pathology
  • Pregnant, breastfeeding, lack of adequate birth control
  • History of intolerance to psilocybin, LSD, or related compounds
  • Drug or alcohol abuse within the past 3 months (excluding tobacco)
  • Urine toxicology positive to drugs of abuse
  • Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine)within 5 half-lives of test days
  • Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks
  • Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks
  • Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in thepast 2 weeks

Study Design

Total Participants: 12
Treatment Group(s): 3
Primary Treatment: Low Dose Psilocybin
Phase: 1
Study Start date:
March 28, 2019
Estimated Completion Date:
June 27, 2023

Connect with a study center

  • VA Connecticut Healthcare System

    West Haven, Connecticut 06516
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.